KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $501.4 million.

  • Novavax's Current Deferred Revenue fell 5558.46% to $501.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.4 million, marking a year-over-year decrease of 5558.46%. This contributed to the annual value of $1.1 billion for FY2024, which is 2991.99% up from last year.
  • Latest data reveals that Novavax reported Current Deferred Revenue of $501.4 million as of Q3 2025, which was down 5558.46% from $513.0 million recorded in Q2 2025.
  • Novavax's Current Deferred Revenue's 5-year high stood at $1.6 billion during Q4 2021, with a 5-year trough of $404.8 million in Q3 2022.
  • Its 5-year average for Current Deferred Revenue is $896.8 million, with a median of $863.5 million in 2023.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 2633138.45% in 2021, then tumbled by 6886.15% in 2022.
  • Over the past 5 years, Novavax's Current Deferred Revenue (Quarter) stood at $1.6 billion in 2021, then tumbled by 65.56% to $549.6 million in 2022, then surged by 57.13% to $863.5 million in 2023, then rose by 29.92% to $1.1 billion in 2024, then plummeted by 55.31% to $501.4 million in 2025.
  • Its Current Deferred Revenue stands at $501.4 million for Q3 2025, versus $513.0 million for Q2 2025 and $517.9 million for Q1 2025.